Purpose: The pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, monitoring, and dosage and administration of enteric-coated (EC) mycophenolate sodium are reviewed.

Please provide your email address to receive an email when new articles are posted on . Patients receiving mycophenolate mofetil combination therapies saw increased seroconversion after a third dose ...

Please provide your email address to receive an email when new articles are posted on . Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves ...

You have full access to this article via your institution. This prospective randomized US trial recruited patients who were about to undergo renal transplantation with a deceased-donor or living-donor ...

Substantial evidence exists that patients with scleroderma have immune dysfunction and autoimmunity, and several studies support the use of immunosuppressive treatment in these patients. Nihtyanova et ...

Children with frequently relapsing or steroid-dependent nephrotic syndrome had a significantly longer relapse-free survival period with tacrolimus than with mycophenolate mofetil. Relapse-free ...

Discover comprehensive details about Mycophenolate Mofetil, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ...

Review the side-effects of Mycophenolate Mofetil as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis. A ...

Up to 40% of patients with IgAN progress to end-stage kidney disease, investigators noted. Mycophenolate mofetil (MMF) reduces the risk of disease progression in patients with immunoglobulin A ...

The most common adverse effects of EC mycophenolate sodium reported in Phase III clinical studies are GI effects, including nausea, vomiting, and diarrhea. [30] GI complaints are some of the most ...